Nataliya Mar • UCI Profiles (original) (raw)

  1. Patterns of immune-related adverse events in patients treated for various cancer types with immune checkpoint inhibitors. Future Oncol. 2026 Jan; 22(1):37-43. Slaught MJ, Kaakour D, Azizi A, Kroening G, Chen WP, Mar N, Valerin JB. PMID: 41423709; PMCID: PMC12773467.
    View in: PubMed Mentions:
  2. Understanding Patient and Oncologist Preferences in the Management of Metastatic Renal Cell Carcinoma. Cancer Treat Res Commun. 2026; 46:101067. Yazdanpanah O, Mahadevan A, Benjamin DJ, Vosoughi E, Raad A, Popal M, Kongtim P, Mar N, Kalebasty AR. PMID: 41496259.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  3. Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience. Cancer Med. 2025 Nov; 14(21):e71327. Lee F, Mahadevan A, Azizi A, Valerin J, Mar N, Jeyakumar D, Dayyani F. PMID: 41187936; PMCID: PMC12585292.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  4. Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma. ESMO Open. 2025 Aug; 10(8):105544. van der Heijden MS, Powles T, Gupta S, Loriot Y, Galsky MD, Valderrama BP, Sridhar SS, Yu EY, Iyer G, Kikuchi E, Castellano D, Hoffman-Censits J, Drakaki A, Mar N, Maroto Rey JP, Vulsteke C, Arafat W, Duran I, Dawson NA, Swami U, Gorla S, Moreno BH, Yu X, Lu YT, Bedke J. PMID: 40795788; PMCID: PMC12361773.
    View in: PubMed Mentions: Translation:HumansCTClinical Trials
  5. Comprehensive Comparison of Somatic, Germline, and Immune Cell Profiles in Upper Tract and Bladder Urothelial Carcinoma. JCO Precis Oncol. 2025 Aug; 9:e2500289. Yuen K, Meagher M, Mercer J, Yilma B, Stoppler M, Fragkogianni S, Mar N, Kalebasty AR, Gupta S, Grivas P, Bagrodia A, Mckay R, Stewart T, Salmasi A. PMID: 40773709.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  6. Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data. Clin Med Insights Oncol. 2025; 19:11795549251341877. Arter ZL, Benjamin DJ, Cao Y, Farias J, Thirumaran RK, Forsyth M, Mar N, Rezazadeh Kalebasty A. PMID: 40538886; PMCID: PMC12177250.
    View in: PubMed Mentions: 1
  7. A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 study. Future Oncol. 2025 Mar; 21(7):749-764. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüs M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, Van der Heijden MS. PMID: 39889805; PMCID: PMC11916366.
    View in: PubMed Mentions: Fields:
  8. Implications and Lessons from the Withdrawal of Sacituzumab Govitecan for Treating Advanced Urothelial Carcinoma. Eur Urol Oncol. 2025 Apr; 8(2):242-244. Benjamin DJ, Rezazadeh Kalebasty A, Mar N. PMID: 39855979.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  9. A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy. Adv Radiat Oncol. 2025 Jan; 10(1):101671. Harada GK, Seyedin SN, Heutlinger O, Azizi A, Hsu A, Rezazadeh A, Daneshvar M, Gin GE, Uchio EM, Giannico GA, Harris JP, Simon AB, Kuo JV, Mar N. PMID: 39655154; PMCID: PMC11626798.
    View in: PubMed Mentions: 1
  10. Safety Analysis of Co-Administration of Radiation Therapy with Enfortumab Vedotin Based Regimens in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2024 Dec; 22(6):102243. Seyedin SN, Harada GK, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, Rezazadeh A, Daneshvar M, Mar N. PMID: 39520850.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  11. The Role of Maximal TURBT in Muscle-Invasive Bladder Cancer: Balancing Benefits in Bladder Preservation and Beyond. Cancers (Basel). 2024 Sep 30; 16(19). Sheybaee Moghaddam F, Dwabe S, Mar N, Safdari L, Sabharwal N, Goldberg H, Daneshvar M, Rezazadeh Kalebasty A. PMID: 39409980; PMCID: PMC11475991.
    View in: PubMed Mentions: 3
  12. Socioeconomic Barriers to Receiving Early Salvage Radiotherapy for Locally Advanced Prostate Adenocarcinoma: A Retrospective Single-Center Study. Cureus. 2024 Sep; 16(9):e68945. Heutlinger O, Azizi A, Harada G, Harris JP, Daneshvar M, Gin G, Uchio E, Mar N, Rezazadeh A, Seyedin SN. PMID: 39381448; PMCID: PMC11460723.
    View in: PubMed Mentions:
  13. Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report. Cureus. 2024 Jul; 16(7):e64781. Seyedin SN, Harada G, Garemanian E, Rafizadeh D, Kaakour D, Dwabe S, Daneshvar M, Mar N. PMID: 39156348; PMCID: PMC11329860.
    View in: PubMed Mentions:
  14. Diversifying editorial boards to mitigate the global burden of genitourinary cancers. Nat Rev Urol. 2024 07; 21(7):385-386. Benjamin DJ, Arter Z, Mar N, Rezazadeh Kalebasty A. PMID: 38429488.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  15. Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D. Eur Urol Oncol. 2025 Jun; 8(3):641-651. Yu EY, Ferrario C, Linch MD, Stoeckle M, Laguerre B, Arranz JA, Todenhöfer T, Fong PC, Piulats JM, Berry W, Emmenegger U, Mourey L, Joshua AM, Mar N, Appleman LJ, Conter HJ, Gravis G, Li XT, Schloss C, Poehlein C, de Bono JS. PMID: 38926066.
    View in: PubMed Mentions: 5 Fields:
    Translation:HumansCTClinical Trials
  16. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024 03 07; 390(10):875-888. Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüs M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS, EV-302 Trial Investigators. PMID: 38446675.
    View in: PubMed Mentions: 365 Fields:
    Translation:HumansCTClinical Trials
  17. Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab. J Clin Oncol. 2024 Apr 20; 42(12):1403-1414. Milowsky MI, O'Donnell PH, Hoimes CJ, Petrylak DP, Flaig TW, Moon HH, Friedlander TW, Mar N, McKay RR, Srinivas S, Gravis G, Ramamurthy C, Bupathi M, Bracarda S, Wright P, Hepp Z, Carret AS, Yu Y, Dillon R, Kataria R, Beaumont JL, Purnajo I, Rosenberg JE. PMID: 38215355; PMCID: PMC11095879.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCTClinical Trials
  18. A case report of challenges in distinguishing gastroesophageal junction hepatoid adenocarcinoma from testicular germ cell tumor: Insights for improved diagnosis with gene expression profiling. SAGE Open Med Case Rep. 2024; 12:2050313X231223469. Yazdanpanah O, Lee FC, Houshyar R, Nourbakhsh M, Mar N. PMID: 38187811; PMCID: PMC10768574.
    View in: PubMed Mentions: 1
  19. Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). Clin Genitourin Cancer. 2024 04; 22(2):217-223. Mar N, Dwabe S, Baranda MN, Zarrabi KK, Eturi A, Gulati S, Parikh M, Seyedin SN, Kalebasty AR. PMID: 38087703.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  20. Drug extravasation with Enfortumab vedotin. J Oncol Pharm Pract. 2023 Oct; 29(7):1789-1792. Grant CR, de Kouchkovsky D, Kalebasty AR, Mar N. PMID: 37401244; PMCID: PMC10612376.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  21. Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2023 09 01; 41(25):4107-4117. O'Donnell PH, Milowsky MI, Petrylak DP, Hoimes CJ, Flaig TW, Mar N, Moon HH, Friedlander TW, McKay RR, Bilen MA, Srinivas S, Burgess EF, Ramamurthy C, George S, Geynisman DM, Bracarda S, Borchiellini D, Geoffrois L, Maroto Rey JP, Ferrario C, Carret AS, Yu Y, Guseva M, Homet Moreno B, Rosenberg JE. PMID: 37369081; PMCID: PMC10852367.
    View in: PubMed Mentions: 100 Fields:
    Translation:Humans
  22. Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma. Cancers (Basel). 2023 May 30; 15(11). Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, Oh DY, Williamson SK, Gajate P, Arkenau HT, Jones RJ, Teo MY, Turan T, McLaughlin RT, Peltier HM, Chong E, Atluri H, Dean JP, Castellano D. PMID: 37296940; PMCID: PMC10251876.
    View in: PubMed Mentions: 1
  23. Combination of Pembrolizumab and Stereotactic Body Radiation Therapy in Recurrent Metastatic Penile Squamous Cell Carcinoma: A Case Study. Biomedicines. 2022 Nov 24; 10(12). Kaakour D, Seyedin S, Houshyar R, Mar N. PMID: 36551787; PMCID: PMC9775235.
    View in: PubMed Mentions: 2
  24. Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma. Clin Med Insights Oncol. 2022; 16:11795549221126252. Benjamin DJ, Mar N, Rezazadeh Kalebasty A. PMID: 36186672; PMCID: PMC9520173.
    View in: PubMed Mentions: 7
  25. Use of immunotherapy in clinical management of genitourinary cancers - a review. Cancer Treat Res Commun. 2022; 31:100564. Mar N, Uchio E, Kalebasty AR. PMID: 35472699.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  26. Late recurrence of localized pure seminoma in prostate gland: A case report. World J Clin Oncol. 2022 Jan 24; 13(1):62-70. Baweja A, Mar N, Rezazadeh Kalebasty A. PMID: 35116233; PMCID: PMC8790299.
    View in: PubMed Mentions: 2
  27. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma. J Oncol Pharm Pract. 2022 Jul; 28(5):1226-1229. Azizi A, Houshyar R, Mar N. PMID: 35043748.
    View in: PubMed Mentions: 3 Fields:
    Translation:Humans
  28. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract. 2022 03; 18(3):197-199. Mar N, Kaakour D, Rezazadeh Kalebasty A. PMID: 34550754.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  29. Immune-Related Meningoencephalitis following Nivolumab in Metastatic Renal Cell Carcinoma. Case Rep Oncol. 2021 May-Aug; 14(2):1051-1058. Shields LBE, Alsorogi MS, Mar N, Rezazadeh Kalebasty A. PMID: 34326741; PMCID: PMC8299396.
    View in: PubMed Mentions: 4
  30. Cutaneous reactions with enfortumab vedotin: A case series and review of the literature. JAAD Case Rep. 2021 Aug; 14:7-9. Dobry AS, Virgen CA, Hosking AM, Mar N, Doan L, Lee B, Smith J. PMID: 34235241; PMCID: PMC8249843.
    View in: PubMed Mentions: 10
  31. Adjuvant pembrolizumab in genomically selected high-risk patients with muscle-invasive bladder cancer. J Oncol Pharm Pract. 2021 Dec; 27(8):2053-2056. Mar N, Kalebasty AR. PMID: 34013824.
    View in: PubMed Mentions: Fields:
    Translation:Humans
  32. Thromboembolic events in metastatic testicular cancer treated with cisplatin-based chemotherapy. World J Clin Oncol. 2021 Mar 24; 12(3):183-194. Shields LBE, Daniels MW, Mar N, Rezazadeh Kalebasty A. PMID: 33767973; PMCID: PMC7968108.
    View in: PubMed Mentions: 6
  33. Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas. JCO Oncol Pract. 2020 12; 16(12):783-789. Mar N, Kalebasty AR, Uchio EM. PMID: 33301698.
    View in: PubMed Mentions: 2 Fields:
    Translation:Humans
  34. Development of carpal tunnel syndrome in association with checkpoint inhibitors. J Oncol Pharm Pract. 2021 Apr; 27(3):764-765. Eisenbud L, Ejadi S, Mar N. PMID: 32819198.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  35. Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab. J Oncol Pharm Pract. 2021 Jan; 27(1):212-215. Baweja A, Mar N. PMID: 32380900.
    View in: PubMed Mentions: 15 Fields:
    Translation:Humans
  36. Management of Urothelial Bladder Cancer in Clinical Practice: Real-World Answers to Difficult Questions. J Oncol Pract. 2019 08; 15(8):421-428. Mar N, Dayyani F. PMID: 31404517.
    View in: PubMed Mentions: 11 Fields:
    Translation:Humans
  37. Use of Neoadjuvant Sunitinib in Renal Cell Carcinoma of a Transplanted Kidney. J Oncol Pract. 2018 10; 14(10):632-634. Mar N, Houshyar R, Jordan M. PMID: 30133347.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  38. Rubinstein-Taybi syndrome - a window into follicular lymphoma biology. Leuk Lymphoma. 2016 12; 57(12):2908-2910. Mar N, Digiuseppe JA, Dailey ME. PMID: 27086936.
    View in: PubMed Mentions: 4 Fields:
    Translation:Humans
  39. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015 Mar; 87(3):220-5. Mar N, Vredenburgh JJ, Wasser JS. PMID: 25601485.
    View in: PubMed Mentions: 57 Fields:
    Translation:HumansCells
  40. Blue toes and a new pair of shoes--challenges in diagnosis and treatment of acute myelogenous leukemia. Am J Hematol. 2013 Dec; 88(12):1090-3. Mar N, Gorgan MA, Dailey ME, Vredenburgh JJ. PMID: 23918652.
    View in: PubMed Mentions: 1 Fields:
    Translation:Humans
  41. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006 Nov; 17(10):1227-9. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW. PMID: 17075324.
    View in: PubMed Mentions: 14 Fields:
    Translation:Humans
  42. IL-15, an immunomodulator of T cell responses in intracellular infection. J Immunol. 1997 Jan 15; 158(2):800-6. Jullien D, Sieling PA, Uyemura K, Mar ND, Rea TH, Modlin RL. PMID: 8992997.
    View in: PubMed Mentions: 42 Fields:
    Translation:HumansCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs